Marco Banini

Stereotactic Body Radiation Therapy and Abiraterone Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate Cancer: A Randomized Phase II Trial (ARTO)

Giulio Francolini, Andrea Gaetano Allegra, Beatrice Detti et al. · Journal of Clinical Oncology · 2023 · 126 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Neutrophil-to-lymphocyte ratio in combination with PD-L1 or lactate dehydrogenase as biomarkers for high PD-L1 non-small cell lung cancer treated with first-line pembrolizumab

Giuseppe Luigi Banna, Diego Signorelli, Giulio Metro et al. · Translational Lung Cancer Research · 2020 · 64 citations · Full text

Medicine, Oncology, Pharmacology +17

Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European cohort

Giulio Metro, Alfredo Addeo, Diego Signorelli et al. · Journal of Thoracic Disease · 2019 · 44 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab

Alex Friedlaender, Giulio Metro, Diego Signorelli et al. · Acta Oncologica · 2020 · 38 citations · Full text

Medicine, Oncology, Pharmacology +14

Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients

Christian Britschgi, Alfredo Addeo, Markus Rechsteiner et al. · Frontiers in Oncology · 2020 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17